An International Survey of Allogeneic Hematopoietic Cell Transplantation for X-Linked Agammaglobulinemia.

Akira NishimuraRamya UppuluriRevathi RajVenkateswaran Vellaichamy SwaminathanYifei ChengRolla F Abu-ArjaBin FuAlexandra LaberkoMichael H AlbertFabian HauckGiorgia BucciolVenetia BigleySuzanne ElcombeGaurav KharyaCornelis Jan H PronkClaudia WehrBénédicte NevenKlaus WarnatzIsabelle MeytsTomohiro MorioAndrew R GenneryHirokazu Kanegane

Published in: Journal of clinical immunology (2023)

Based on the concept in which IgRT is the standard treatment for XLA, HCT may be an effective and safe alternative treatment option for XLA patients, and IgRT can be discontinued following transplantation. It is ideal to perform HCT in XLA patients for whom transplantation is indicated before they develop organ damage.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
prognostic factors
patient reported outcomes
mesenchymal stem cells
cell proliferation
signaling pathway